To explore the reasons why women do not pursue thirdline therapy for overactive bladder (OAB). MATERIALS AND METHODS: This is a qualitative research project aiming to identify barriers to treatment with intradetrusor onabotulinumtoxinA, sacral neuromodulation, or percutaneous nerve stimulation. Initial data collection included a chart review of English-speaking women aged 18 to 80 with a diagnosis of OAB who attended an office visit in the departments of urogynecology or urology at our institution between January 2017 and March 2018. Of these women, patients counseled for third-line therapy, refractory to two or more medications, or lost to follow up after initiating a second medication were considered study candidates. Previous recipients of third-line therapy were excluded. Potential study candidates were then randomly invited to participate in a semi-structured phone interview using a beta-tested interview guide. Interview topics included medical knowledge and beliefs, quality of life, and treatment experience. The interviews were then transcribed into text. Using grounded theory, three independent researchers with experience in qualitative methodology reviewed the transcriptions and coded participant responses thematically. Interviews continued to be performed until no new themes were identified (theoretical saturation). Each coder reviewed the themes identified by the other members of the research team and any coding discrepancies were discussed amongst the group for internal validation. RESULTS: On chart review, 381 English-speaking women aged 18 to 80 with a diagnosis of OAB were evaluated in the office from January 2017 to March 2018. 66 patients (17.3%) had already received thirdline therapy. 56 women qualified for our study. The average interview length was approximately 30 minutes and theoretical saturation occurred at 30 interviews. Insufficient or deficient in-office education was the most common modifiable barrier identified by the women interviewed. Many participants would have preferred to be educated about third-line options earlier-perhaps beginning at the first office visit. Other modifiable barriers included negative experiences with previous treatments or evaluation techniques, provider sex, and wait times. Non-modifiable barriers included desire for non-invasive interventions, fear of side effects, negative anecdotes from friends, cost, concern about repeat procedures, self-defined readiness, medical co-morbidities, and media portrayal of onabotulinumtoxinA. CONCLUSION: In-office education is of paramount importance to women suffering from refractory OAB. Timing of counseling is of equal importance. Third-line therapy counseling should be incorporated into the initial office visit. This may improve patient compliance and graduation to advanced therapy in women who later go on to develop refractory symptoms.
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16A Long term clinical outcomes following the

OBJECTIVES:
The goal of this study is to assess long term outcomes for trans-obturator post-anal sling (TOPAS) procedure for the treatment of fecal incontinence. The TOPAS is percutaneous procedure whereby a synthetic polypropylene mesh is placed in a slinglike position behind the anus and brought up through the ischiorectal fossa and the medial obturator foramen. Studies to date have shown outcomes at 12 and 24 months postoperatively that are comparable to those seen with sacral neuromodulation but there are limited studies looking at outcomes beyond 24 months. MATERIALS AND METHODS: A retrospective cohort study was conducted. All patients who underwent the TOPAS procedure at a single institution were identified through review of Current Procedural Terminology codes and operative reports were reviewed to ensure accuracy. At baseline patients completed the Pelvic Floor Distress Inventory . Medical records were reviewed to assess for symptom resolution, symptom improvement, and complications. RESULTS: We identified 133 patients who underwent the TOPAS procedure. Patients were a median of 62 years at the time of surgery (IQR 53-69). At baseline patients had a median PFDI-20 score of 104.16 (IQR 71.88-151.05) and median CRAD-8 score of 46.88 (IQR 25.00-59.38). In addition to fecal incontinence, most patients reported urinary and prolapse symptoms (91.8% and 72.8% respectively). Before undergoing the TOPAS procedure, only 6 respondents (4.5%) had undergone advanced treatment for fecal incontinence such as sacral neuromodulation or sphincteroplasty. After surgery, patients were followed in clinic for a median of one year (IQR 0-4). Among patients who received treatment, 93 (69.2%) had significant improvement in symptoms. There were 62 patients (46.6%) that were followed in clinic for more than 2 years. Among patients with long-term clinical follow up, we found similar rates of success as seen in the overall cohort. Among those followed in clinic for more than 2 years, 44 (71.0%) reported significant improvement in symptoms. There were 19 patients (14.3%) with at least five years of clinical follow up and among those patients, 15 (78.1%) reported significant improvement in symptoms. Only 31 (23.3%) required subsequent therapy beyond dietary modifications treatment of fecal incontinence postoperatively. No adverse events were identified with long term follow up and no patients had evidence of mesh erosion, rectal obstruction, or need for surgical revision. CONCLUSION: While studies to date have shown high rates of success for the TOPAS for the treatment of fecal incontinence in the short term, this is the first study to look at outcomes beyond two years. Our findings suggest that the TOPAS procedure remains a safe and effective therapy for the treatment of fecal incontinence with outcomes similar to those seen with other third line therapies for the treatment of fecal incontinence.
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